Long-Term Measurement of Tremor

  • S. Spieker
  • E. Scholz
  • M. Bacher
  • J. Dichgans
Conference paper

Abstract

The development of new treatment strategies for tremor requires an objective and reproducible method for tremor quantification. Subjective rating, even using standardized scores, very often leads to contradictory results between patients and physicians. Objective methods have so far usually only been performed during short periods and therefore have not taken the high variability of tremor into account.

Keywords

Placebo Neurol NMDA Piperidine Budipine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bacher M, Scholz E, Diener HC (1989) 24 Hour continuous tremor quantification based on EMG recording. Electroencephalogr Clin Neurophysiol 72:176–183PubMedCrossRefGoogle Scholar
  2. 2.
    Scholz E, Bacher M, Diener HC, Dichgans J (1988) Twenty-four-hour tremor recordings in the evaluation of the treatment of Parkinson’s disease. J Neurol 235:475–484PubMedCrossRefGoogle Scholar
  3. 3.
    Elble RJ and Koller WC (1990) Tremor. John Hopkins University Press, BaltimoreGoogle Scholar
  4. 4.
    Jellinger K, Bliesath H (1987) Adjuvant treatment of Parkinson’s disease with budipine: a double-blind trial versus placebo. J Neurol 234:280–282PubMedCrossRefGoogle Scholar
  5. 5.
    Klockgether T, Jacobsen P, Löschmann P-A, Turski L (1992) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm PD-Sect Park Dis Dement Sect 5:101–106CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • S. Spieker
  • E. Scholz
  • M. Bacher
  • J. Dichgans

There are no affiliations available

Personalised recommendations